Meeting
2014 Genitourinary Cancers Symposium
Circulating tumor cell kinetics in mRCC patients treated with sunitinib.
Authors
Kriti Mittal
Cleveland Clinic, Cleveland, OH
Kriti Mittal , Anthony Williams , Siddarth Rawal , Vyshak Alva Venur , Bo Lu , Jorge Torres-Munoz , Ernest C. Borden , Zheng Ao , Martin OMalley , Laura S. Wood , Siyang Zheng , Ram H Datar , Yu-Chong Tai , Richard J. Cote , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 481)
DOI
10.1200/jco.2014.32.4_suppl.481
Abstract #
481
Poster Bd #
F14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.
First Author: Renee Maria Saliby
Poster
2022 ASCO Annual Meeting
CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.
First Author: Carolina Reduzzi
Poster
2017 Genitourinary Cancers Symposium
Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC.
First Author: Yoshihiko Tomita
Poster
2017 Genitourinary Cancers Symposium
Analysis of predictive clinical markers of outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with tyrosine-kinases inhibitors (TKI) in first line: A C Camargo Cancer Center experience.
First Author: Camila Nassif Martins Ferreira